Sou Hu Cai Jing·2025-07-23 12:19Core Viewpoint - The stock of Zhaoyan New Drug closed at 27.33 yuan, up 6.43%, with a rolling PE ratio of 52.87, marking a new low in 405 days, and a total market capitalization of 20.483 billion yuan [1]. Group 1: Company Performance - As of the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.12 million yuan, a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. - The company specializes in non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1]. Group 2: Market Position - Zhaoyan New Drug's PE ratio of 52.87 is higher than the industry average of 45.40 and the industry median of 52.21, ranking 30th among its peers [2]. - A total of 17 institutions hold shares in Zhaoyan New Drug, with a combined holding of 10.9687 million shares valued at 231 million yuan [1].